To evaluate whether KCTD15 silencing could improve the action of drugs commonly used in the treatment of breast cancer, we decided to estimate the in vitro effect of Doxorubicin, a generic chemotherapeutic agent [31], and the Trastuzumab, a drug specifically used in the treatment of HER2+ breast cancer patients [35]. The gene discussed is KCTD15; the disease is breast carcinoma.